Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation

Atrial fibrillation (AF) constitutes the most common, major cardiac arrhythmia worldwide, with an estimated prevalence in the United States equal to 2.3 million affected subjects, projected to increase to 5.6 million by 2050.1 Hypertension and background heart disease (mainly, congestive heart failure) or valve disease represent main risk factors for AF development.1 Other modifiable risk factors are sedentary lifestyle, smoking, obesity, diabetes mellitus, and obstructive sleep apnea.2 AF is associated with a significant increase in the risk for all-cause and cardiovascular death, ischemic stroke, heart failure (HF), ischemic heart disease, chronic kidney disease (CKD), and sudden cardiac death, as shown in a former meta-analysis of 104 cohorts in a total of almost 10 million subjects.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research